Ligand Pharmaceuticals Inc (LGND)
85.77
+0.48
(+0.56%)
USD |
NASDAQ |
May 15, 16:00
85.72
-0.04
(-0.05%)
After-Hours: 20:00
Ligand Pharmaceuticals Accounts Receivable (Quarterly): 28.44M for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 28.44M |
December 31, 2023 | 32.92M |
September 30, 2023 | 36.00M |
June 30, 2023 | 27.99M |
March 31, 2023 | 29.19M |
December 31, 2022 | 30.42M |
September 30, 2022 | 65.17M |
June 30, 2022 | 62.31M |
March 31, 2022 | 41.80M |
December 31, 2021 | 85.45M |
September 30, 2021 | 64.34M |
June 30, 2021 | 58.16M |
March 31, 2021 | 54.44M |
December 31, 2020 | 56.85M |
September 30, 2020 | 32.91M |
June 30, 2020 | 41.87M |
March 31, 2020 | 39.51M |
December 31, 2019 | 30.39M |
September 30, 2019 | 21.96M |
June 30, 2019 | 20.26M |
March 31, 2019 | 26.62M |
December 31, 2018 | 55.85M |
September 30, 2018 | 46.98M |
June 30, 2018 | 42.00M |
March 31, 2018 | 37.11M |
Date | Value |
---|---|
December 31, 2017 | 25.60M |
September 30, 2017 | 12.82M |
June 30, 2017 | 13.46M |
March 31, 2017 | 7.057M |
December 31, 2016 | 14.70M |
September 30, 2016 | 6.586M |
June 30, 2016 | 9.966M |
March 31, 2016 | 11.78M |
December 31, 2015 | 6.17M |
September 30, 2015 | 5.517M |
June 30, 2015 | 5.532M |
March 31, 2015 | 7.423M |
December 31, 2014 | 12.63M |
September 30, 2014 | 5.812M |
June 30, 2014 | 3.133M |
March 31, 2014 | 4.673M |
December 31, 2013 | 2.222M |
September 30, 2013 | 5.507M |
June 30, 2013 | 0.699M |
March 31, 2013 | 4.622M |
December 31, 2012 | 4.589M |
September 30, 2012 | 2.157M |
June 30, 2012 | 0.817M |
March 31, 2012 | 1.992M |
December 31, 2011 | 6.11M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
20.26M
Minimum
Jun 2019
85.45M
Maximum
Dec 2021
43.02M
Average
37.75M
Median
Accounts Receivable (Quarterly) Benchmarks
ANI Pharmaceuticals Inc | 172.42M |
Annovis Bio Inc | -- |
ADMA Biologics Inc | 49.62M |
United Therapeutics Corp | 307.30M |
Blueprint Medicines Corp | 60.05M |